HRP20151130T1 - Fuzijski protein koji sadrži domenu kaspaze i vezujuä†u domenu nuklearnog hormonskog receptora te uz njega vezani postupci i uporabe - Google Patents
Fuzijski protein koji sadrži domenu kaspaze i vezujuä†u domenu nuklearnog hormonskog receptora te uz njega vezani postupci i uporabe Download PDFInfo
- Publication number
- HRP20151130T1 HRP20151130T1 HRP20151130TT HRP20151130T HRP20151130T1 HR P20151130 T1 HRP20151130 T1 HR P20151130T1 HR P20151130T T HRP20151130T T HR P20151130TT HR P20151130 T HRP20151130 T HR P20151130T HR P20151130 T1 HRP20151130 T1 HR P20151130T1
- Authority
- HR
- Croatia
- Prior art keywords
- caspase
- domain
- ligand
- fusion protein
- receptor
- Prior art date
Links
- 102000007399 Nuclear hormone receptor Human genes 0.000 title claims 16
- 108020005497 Nuclear hormone receptor Proteins 0.000 title claims 16
- 108020001507 fusion proteins Proteins 0.000 title claims 16
- 102000037865 fusion proteins Human genes 0.000 title claims 16
- 102000011727 Caspases Human genes 0.000 title claims 12
- 108010076667 Caspases Proteins 0.000 title claims 12
- 238000000034 method Methods 0.000 title claims 5
- 239000003446 ligand Substances 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 8
- 230000006907 apoptotic process Effects 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000004091 Caspase-8 Human genes 0.000 claims 4
- 108090000538 Caspase-8 Proteins 0.000 claims 4
- 102000004039 Caspase-9 Human genes 0.000 claims 4
- 108090000566 Caspase-9 Proteins 0.000 claims 4
- 102000015694 estrogen receptors Human genes 0.000 claims 4
- 108010038795 estrogen receptors Proteins 0.000 claims 4
- 108020001756 ligand binding domains Proteins 0.000 claims 4
- 102100032187 Androgen receptor Human genes 0.000 claims 2
- 108090000397 Caspase 3 Proteins 0.000 claims 2
- 102000004018 Caspase 6 Human genes 0.000 claims 2
- 108090000425 Caspase 6 Proteins 0.000 claims 2
- 108090000567 Caspase 7 Proteins 0.000 claims 2
- 102000004068 Caspase-10 Human genes 0.000 claims 2
- 108090000572 Caspase-10 Proteins 0.000 claims 2
- 102000004066 Caspase-12 Human genes 0.000 claims 2
- 108090000570 Caspase-12 Proteins 0.000 claims 2
- 102000004046 Caspase-2 Human genes 0.000 claims 2
- 108090000552 Caspase-2 Proteins 0.000 claims 2
- 102100029855 Caspase-3 Human genes 0.000 claims 2
- 102100038902 Caspase-7 Human genes 0.000 claims 2
- 241000252212 Danio rerio Species 0.000 claims 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000003998 progesterone receptors Human genes 0.000 claims 2
- 108090000468 progesterone receptors Proteins 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
- C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (17)
1. Fuzijski protein koji obuhvaća
(a) domenu kaspaze koja može inducirati apoptozu i
(b) domenu koja kao ligand veže nuklearni hormonski receptor, pri čemu se domena koja kao ligand veže nuklearni hormonski receptor aktivira nakon vezanja liganda za domenu koja kao ligand veže nuklearni receptor.
2. Fuzijski protein prema zahtjevu 1,
a) gdje nakon što se ligand izloži domeni koja kao ligand veže nuklearni hormonski receptor, fuzijski protein može inducirati apoptozu u stanici, poželjno eukariotskoj stanici, koja eksprimira fuzijski protein; i/ili
b) gdje domena kaspaze jest kaspaza, izabrana iz grupe koja obuhvaća Kaspazu-2, Kaspazu-3, Kaspazu-6, Kaspazu-7, Kaspazu-8, Kaspazu-9, Kaspazu-10, Kaspazu-12, najpoželjnije Kaspazu-8 ili Kaspazu-9 i/ili;
c) gdje se nuklearni hormonski receptor izabire iz grupe koja obuhvaća Estrogenski receptor, progesteronski receptor, glukokortikoidni receptor, androgeni receptor i/ili
d) gdje je domena koja kao ligand veže nuklearni hormonski receptor vezana za N-kraj ili C-kraj domene kaspaze, poželjno gdje je domena koja kao ligand veže nuklearni hormonski receptor vezana za C-kraj domene kaspaze; i/ili
e) gdje je domena koja kao ligand veže nuklearni hormonski receptor vezana izravno za domenu kaspaze.
3. Fuzijski protein prema zahtjevu 2,
a) gdje je kaspaza od sisavaca, kaspaza od glodavaca ili humana kaspaza, izabrana iz grupe koja obuhvaća Kaspazu-2, Kaspazu-3, Kaspazu-6, Kaspazu-7, Kaspazu-8, Kaspazu-9, Kaspazu-10, Kaspazu-12, najpoželjnije Kaspazu-8 ili Kaspazu-9; i/ili
b) gdje domena kaspaze obuhvaća ili se sastoji od aminokiselinske sekvence SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 67 ili SEQ ID NO: 68.
4. Fuzijski protein prema zahtjevu 2,
a) gdje nuklearni hormonski receptor jest Estrogenski receptor, i/ili
b) gdje receptor jest nuklearni hormonski receptor od sisavca ili humani, izabran iz grupe koja obuhvaća Estrogenski receptor, progesteronski receptor, glukokortikoidni receptor, androgeni receptor i mutant ER(T2) Estrogenskog receptora definirano u SEQ ID NO: 80.
5. Fuzijski protein prema zahtjevu 1 ili 4, gdje domena koja kao ligand veže nuklearni hormonski receptor jest vezana za domenu kaspaze preko poveznice (linker), poželjno
a) gdje se linker sastoji od 1 do 100 aminokiselinskih ostataka, posebno se u biti sastoji od neutralnih aminokiselina; i/ili
b) gdje linker obuhvaća dio nuklearnog hormonskog receptora D i F sekvenca domene koje su bočne domeni koja veže ligand.
6. Fuzijski protein prema bilo kojem od zahtjeva 1 do 5 koji obuhvaća aminokiselinsku sekvencu, izabranu iz grupe koja obuhvaća SEQ ID NO: 20, SEQ ID NO: 23, SEQ ID NO: 29, SEQ ID NO: 32 ili SEQ ID NO: 37.
7. Nukleinska kiselina koja kodira fuzijski protein prema bilo kojem od zahtjeva 1 do 6.
8. Vektor koji obuhvaća nukleinsku kiselinu prema zahtjevu 7.
9. Stanica koja obuhvaća nukleinsku kiselinu prema zahtjevu 7 i/ili vektor prema zahtjevu 8.
10. Postupak proizvodnje fuzijskog proteina prema bilo kojem od zahtjeva 1 do 6 koji obuhvaća
- uzgoj kulture stanica prema zahtjevu 9 pod uvjetima koji su pogodni za proizvodnju fuzijskog proteina.
11. Ne-humani transgenični organizam, poželjno ne-humani transgenični sisavac ili riba zebrica, koji sadrži nukleinsku kiselinu prema zahtjevu 7 ili vektor prema zahtjevu 8.
12. Uporaba fuzijskog proteina prema bilo kojem od zahtjeva 1 do 6 za ligandom-posredovanu indukciju apoptoze stanice, poželjno eukariotske stanice, još poželjnije stanice sisavca ili stanice ribe zebrice, posebno humane stanice, gdje uporaba ne uključuje terapijski i/ili dijagnostički postupak.
13. Uporaba prema zahtjevu 12 za ispitivanje funkcije stanica, tkiva i/ili organa, posebno za ispitivanje funkcije stanica u različitim stupnjevima razvoja ili kao model bolesti.
14. In vitro postupak za indukciju apoptoze stanice koja eksprimira fuzijski protein prema bilo kojem od zahtjeva 1 do 6, postupak obuhvaća
- dovođenje u doticaj stanične domene koja kao ligand veže nuklearni hormonski receptor s ligandom koji može inducrati apoptozu stanice.
15. In vitro postupak za identifikaciju liganda za domenu koja kao ligand veže nuklearni hormonski receptor ili njegove funkcionalno aktivne varijante, postupak obuhvaća
- dovođenje u doticaj stanične domene koja kao ligand veže nuklearni hormonski receptor prema zahtjevu 9 sa supstancom; i
- identifikacija supstance kao liganda, ovisno o sposobnosti indukcije apoptoze stanice.
16. Fuzijski protein prema bilo kojem od zahtjeva 1 do 6, nukleinska kiselina prema zahtjevu 7, vektor prema zahtjevu 8 i/ili stanica prema zahtjevu 9 za uporabu kao lijek.
17. Fuzijski protein prema bilo kojem od zahtjeva 1 do 6, nukleinska kiselina prema zahtjevu 7, vektor prema zahtjevu 8 i/ili stanica prema zahtjevu 9 za uporabu u liječenju bolesti gdje je potrebno pojačati apoptozu, posebno za liječenje raka ili kod ili nakon transplantacije, posebno kao sigurnosni mehanizam.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07012138A EP2006376A1 (en) | 2007-06-21 | 2007-06-21 | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
| PCT/EP2008/005013 WO2008155133A2 (en) | 2007-06-21 | 2008-06-20 | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
| EP08784530.1A EP2173869B1 (en) | 2007-06-21 | 2008-06-20 | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151130T1 true HRP20151130T1 (hr) | 2015-12-18 |
Family
ID=38323998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151130TT HRP20151130T1 (hr) | 2007-06-21 | 2015-10-26 | Fuzijski protein koji sadrži domenu kaspaze i vezujuä†u domenu nuklearnog hormonskog receptora te uz njega vezani postupci i uporabe |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8530168B2 (hr) |
| EP (2) | EP2006376A1 (hr) |
| DK (1) | DK2173869T3 (hr) |
| ES (1) | ES2553170T3 (hr) |
| HR (1) | HRP20151130T1 (hr) |
| HU (1) | HUE025829T2 (hr) |
| PL (1) | PL2173869T3 (hr) |
| PT (1) | PT2173869E (hr) |
| WO (1) | WO2008155133A2 (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| CA2887642A1 (en) * | 2012-11-02 | 2014-05-08 | Genesys Research Institute | Compositions and methods for auditory therapy |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US9434935B2 (en) * | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| EP2970372B1 (en) | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
| AU2014274916B2 (en) | 2013-06-05 | 2019-10-31 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| AU2015341481C1 (en) | 2014-11-03 | 2021-09-16 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T cell receptors directed against Bob1 and uses thereof |
| CA3022129A1 (en) | 2016-06-17 | 2017-12-21 | Medigene Immunotherapies Gmbh | T cell receptors and uses thereof |
| WO2018157000A1 (en) * | 2017-02-23 | 2018-08-30 | Olema Pharmaceuticals, Inc. | Compositions and methods for regulating immune system activity |
| TWI731268B (zh) * | 2017-09-29 | 2021-06-21 | 財團法人國家衛生研究院 | 可增強抗腫瘤與抗病毒ｔ細胞存活與其功能性之方法與組合物 |
| WO2019099769A1 (en) * | 2017-11-16 | 2019-05-23 | The Johns Hopkins University | Anastasis biosensor caspase tracker |
| AU2019225798B2 (en) | 2018-02-26 | 2023-05-18 | Medigene Immunotherapies Gmbh | Nyeso tcr |
| WO2020030631A1 (en) | 2018-08-06 | 2020-02-13 | Medigene Immunotherapies Gmbh | Ha-1 specific t cell receptors and their use |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| EP3947435A1 (en) | 2019-04-04 | 2022-02-09 | Medigene Immunotherapies GmbH | Magea1 specific t cell receptors and their use |
| WO2021005108A1 (en) | 2019-07-09 | 2021-01-14 | Medigene Immunotherapies Gmbh | Magea10 specific t cell receptors and their use |
| EP4061827A1 (en) | 2019-11-18 | 2022-09-28 | BioNTech SE | Prame tcr receptors and uses thereof |
| US20210222128A1 (en) | 2020-01-22 | 2021-07-22 | Massachusetts Institute Of Technology | Inducible tissue constructs and uses thereof |
| WO2022036068A1 (en) * | 2020-08-13 | 2022-02-17 | A2 Biotherapeutics, Inc. | Gene fusions for control of genetically modified cells |
| BR112023005318A2 (pt) | 2020-09-24 | 2023-04-25 | Medigene Immunotherapies Gmbh | Receptores de célula t específicos de prame e uso dos mesmos |
| KR20230111186A (ko) | 2020-09-24 | 2023-07-25 | 메디진 이뮤노테라피스 게엠바하 | Mage-a3 특이적 t 세포 수용체 및 그의 용도 |
| EP4334331A1 (en) | 2021-05-07 | 2024-03-13 | Medigene Immunotherapies GmbH | Combination of prame specific t cell receptors and chimeric co-stimulatory receptors |
| WO2023025779A1 (en) | 2021-08-25 | 2023-03-02 | Medigene Immunotherapies Gmbh | Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors |
| WO2023175069A1 (en) | 2022-03-16 | 2023-09-21 | Medigene Immunotherapies Gmbh | Tcr constant region pairing library for pramevld tcrs |
| WO2024041761A1 (en) | 2022-08-23 | 2024-02-29 | Medigene Immunotherapies Gmbh | Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptors |
| WO2024163957A1 (en) * | 2023-02-02 | 2024-08-08 | Senti Biosciences, Inc. | Sustained transgene expression of modified ert2 peptide-suicide protein fusion polypeptides |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5698765A (en) * | 1991-12-02 | 1997-12-16 | The Ontario Cancer Institute | Mouse having a disrupted CD4 gene |
| WO1993018144A1 (en) * | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
| US5625122A (en) * | 1992-04-24 | 1997-04-29 | The Ontario Cancer Institute | Mouse having a disrupted lck gene |
| JP3741447B2 (ja) * | 1992-10-23 | 2006-02-01 | 中外製薬株式会社 | エンドセリン−１遺伝子の機能が欠損したマウス |
| US6399327B1 (en) * | 1995-07-16 | 2002-06-04 | Yeda Research And Development Co. Ltd. | Modulators of the function of FAS receptors and other proteins |
| FR2745008A1 (fr) * | 1996-02-20 | 1997-08-22 | Ass Pour Le Dev De La Rech En | Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre |
| DE19625049A1 (de) | 1996-06-22 | 1998-01-02 | Inst Pflanzengenetik & Kultur | Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält |
| NZ336813A (en) | 1997-02-18 | 2000-02-28 | Ludwig Inst Cancer Res | Transgenic animal with recombinant vascular endothelial growth factor B (VEGF-B) DNA and uses in the promotion of growth of new blood vessels |
| AU1441301A (en) | 1999-10-29 | 2001-05-14 | Nexia Biotechnologies, Inc. | Transgenic animal production using lopu-derived oocytes |
| US20040180828A1 (en) * | 2003-01-30 | 2004-09-16 | Yigong Shi | Caspase-9 : BIR domain of XIAP complexes and methods of use |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
-
2007
- 2007-06-21 EP EP07012138A patent/EP2006376A1/en not_active Withdrawn
-
2008
- 2008-06-20 US US12/665,680 patent/US8530168B2/en active Active
- 2008-06-20 DK DK08784530.1T patent/DK2173869T3/en active
- 2008-06-20 HU HUE08784530A patent/HUE025829T2/en unknown
- 2008-06-20 ES ES08784530.1T patent/ES2553170T3/es active Active
- 2008-06-20 WO PCT/EP2008/005013 patent/WO2008155133A2/en active Application Filing
- 2008-06-20 PT PT87845301T patent/PT2173869E/pt unknown
- 2008-06-20 PL PL08784530T patent/PL2173869T3/pl unknown
- 2008-06-20 EP EP08784530.1A patent/EP2173869B1/en active Active
-
2015
- 2015-10-26 HR HRP20151130TT patent/HRP20151130T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2173869B1 (en) | 2015-08-12 |
| HUE025829T2 (en) | 2016-04-28 |
| US20110023137A1 (en) | 2011-01-27 |
| PL2173869T3 (pl) | 2016-04-29 |
| US8530168B2 (en) | 2013-09-10 |
| EP2173869A2 (en) | 2010-04-14 |
| WO2008155133A2 (en) | 2008-12-24 |
| EP2006376A1 (en) | 2008-12-24 |
| DK2173869T3 (en) | 2015-11-16 |
| WO2008155133A3 (en) | 2009-04-02 |
| ES2553170T3 (es) | 2015-12-04 |
| PT2173869E (pt) | 2015-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151130T1 (hr) | Fuzijski protein koji sadrži domenu kaspaze i vezujuä†u domenu nuklearnog hormonskog receptora te uz njega vezani postupci i uporabe | |
| Chelur et al. | Targeted cell killing by reconstituted caspases | |
| Tian et al. | Strategies for site-specific recombination with high efficiency and precise spatiotemporal resolution | |
| Le Menuet et al. | The neuronal mineralocorticoid receptor: from cell survival to neurogenesis | |
| Arbo et al. | Therapeutic actions of translocator protein (18 kDa) ligands in experimental models of psychiatric disorders and neurodegenerative diseases | |
| Reinick et al. | Identification of an MRAP-independent melanocortin-2 receptor: functional expression of the cartilaginous fish, Callorhinchus milii, melanocortin-2 receptor in CHO cells | |
| Nakayama et al. | No privacy, a Xenopus tropicalis mutant, is a model of human Hermansky-Pudlak syndrome and allows visualization of internal organogenesis during tadpole development | |
| Zsombok et al. | Basophilia, acidophilia and argyrophilia of “dark”(compacted) neurons during their formation, recovery or death in an otherwise undamaged environment | |
| DE69738072T2 (de) | Modifizierte steroid-hormon rezeptoren | |
| Jones et al. | Auxin‐binding proteins and their possible roles in auxin‐mediated plant cell growth | |
| Huang et al. | Z-REX: shepherding reactive electrophiles to specific proteins expressed tissue specifically or ubiquitously, and recording the resultant functional electrophile-induced redox responses in larval fish | |
| Grabher et al. | Efficient activation of gene expression using a heat-shock inducible Gal4/Vp16-UAS system in medaka | |
| Velazco-Mendoza et al. | The first mating experience induces new neurons in the olfactory bulb in male mice | |
| Huckle | Cell-and tissue-based models for study of placental development | |
| Mahapatra et al. | Protein S-nitrosylation: Nitric oxide signalling during anuran tail regression | |
| Nguyen | The (pro) renin receptor in health and disease | |
| Grohmann et al. | BAC transgenic mice to study the expression of P2X2 and P2Y1 receptors | |
| Mella-Alvarado et al. | Tissue and cell-specific transcriptional activity of the human cytomegalovirus immediate early gene promoter (UL123) in zebrafish | |
| US8476484B2 (en) | Transgenic clawed frog embryos and use thereof as detectors of endocrine disrupters in the environment | |
| Allen et al. | Distribution of cells expressing human renin-promoter activity in the brain of a transgenic mouse | |
| CN110095610A (zh) | 一种高通量蛋白质分析方法及其适用文库 | |
| CN113981001A (zh) | 一种组织内可视化邻近标记方法 | |
| US8236937B2 (en) | Methods and compositions for the detection and isolation of ligands | |
| CN100355888C (zh) | 转基因斑马鱼、基因片段和转基因斑马鱼的生产方法 | |
| Potokar et al. | Subcellular localization of Apaf-1 in apoptotic rat pituitary cells |